Skip to main content

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Publication ,  Journal Article
Ettinger, DS; Wood, DE; Akerley, W; Bazhenova, LA; Borghaei, H; Camidge, DR; Cheney, RT; Chirieac, LR; D'Amico, TA; Dilling, TJ; Dobelbower, MC ...
Published in: J Natl Compr Canc Netw
March 2016

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

March 2016

Volume

14

Issue

3

Start / End Page

255 / 264

Location

United States

Related Subject Headings

  • Taxoids
  • Survival Rate
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Nivolumab
  • Lung Neoplasms
  • Immunotherapy
  • Immunosuppressive Agents
  • Humans
  • Docetaxel
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., … Hughes, M. (2016). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw, 14(3), 255–264. https://doi.org/10.6004/jnccn.2016.0031
Ettinger, David S., Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, et al. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.J Natl Compr Canc Netw 14, no. 3 (March 2016): 255–64. https://doi.org/10.6004/jnccn.2016.0031.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar;14(3):255–64.
Ettinger, David S., et al. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.J Natl Compr Canc Netw, vol. 14, no. 3, Mar. 2016, pp. 255–64. Pubmed, doi:10.6004/jnccn.2016.0031.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar;14(3):255–264.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

March 2016

Volume

14

Issue

3

Start / End Page

255 / 264

Location

United States

Related Subject Headings

  • Taxoids
  • Survival Rate
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Nivolumab
  • Lung Neoplasms
  • Immunotherapy
  • Immunosuppressive Agents
  • Humans
  • Docetaxel